Plus Therapeutics shares surge 10.30% premarket after CNSide subsidiary secures Humana coverage for 67 million patients with CNSide CSF assay.

Plus Therapeutics (NASDAQ: PSTV) surged 10.30% in premarket trading following the announcement that its subsidiary, CNSide Diagnostics, secured a national coverage agreement with Humana for its CNSide® Cerebrospinal Fluid Assay. The deal, effective October 29, 2025, expands test coverage to 67 million people in the U.S., including 16 million newly added under Humana’s policy. The assay, with 92% sensitivity and 95% specificity, has been used in over 11,000 tests since 2020, influencing treatment decisions in 90% of cases. The partnership underscores the test’s clinical validation and commercial potential, bolstering investor confidence in CNSide’s market expansion and Plus Therapeutics’ ability to scale its diagnostic solutions for metastatic central nervous system cancers.